摘要 |
<p>The present invention relates to novel heterocyclic compounds, their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxides, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The present invention more particularly relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1), their analogs, their tautomers, their enantiomers, their diastereomers, their regioisomers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxide, their pharmaceutically acceptable solvates and the pharmaceutical compositions containing them. The groups X, Ar, Y, P and R1-R4 are defined in claim 1.</p> |
申请人 |
GLENMARK PHARMACEUTICALS S.A. |
发明人 |
GOPALAN, BALASUBRAMANIAN;GHARAT, LAXMIKANT, ATMARAM;LAKDAWALA, AFTAB, DAWOODBHAI;KARAUNAKARAN, USHA |